

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: [Koios Beverage Corp.](#) (the “Issuer”).

Trading Symbol: [KBEV](#)

Number of Outstanding Listed Securities: [58,410,160 common shares were issued and outstanding as of November 30, 2018](#)

Date: [December 18, 2018 \(for the month of November, 2018\)](#)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

[The Issuer, through its wholly-owned subsidiary Koios, Inc. \(“Koios”\), is an emerging functional beverage company which has an available distribution network of more than 2,000 retail locations across the United States in which to sell its products. Koios uses a proprietary blend of nootropics and natural organic](#)

compounds to enhance human productivity without using harmful chemicals or stimulants. Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity. Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain. The Issuer recently launched a wholly owned subsidiary, Cannavated Beverages Co. to develop a line of cannabis infused, brain-healthy drinks for the legal marijuana market.

During the month of **November 2018**, the Issuer announced that it would be initiating a clinical study into the impact of CBD on the human brain. This study will complement the clinical study the Issuer currently has underway studying the impact of its nootropic supplements on the human brain. Both studies are being conducted by NeuraPerformance/Neurooptimize Brain Center, the go-to brain lab and physiotherapy clinic for Colorado's elite athletes, including the Denver Broncos football team.

The Issuer also provided a corporate update to inform shareholders of its progress during its initial six months of operations since retail sales commenced in May 2018 and advised of the appointment of Chris Koons, a craft-beverage strategist to the Issuer's Advisory Board.

The Issuer continues to seek opportunities to expand its brand and increase distribution in Canada and the United States.

2. Provide a general overview and discussion of the activities of management.

During the month of **November 2018**, management's principal activities consisted of:

- expanding its product line and working with distributors to sell its products;
- expanding e-commerce and direct to consumer and distribution platforms;
- initiating a clinical study to be conducted by NeuraPerformance/Neurooptimize Brain Center by into the impact of CMD on the human brain;
- appointing Chris Koons, the co-founder of Rocky Mountain Soda and a craft-beverage strategist to the Issuer's Advisory Board; and
- general management and administrative matters.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer's wholly owned subsidiary Koios has continued the sale of its Nootropic Drinks and Nootropic Powder supplements.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of **November 2018**.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer, the Issuer's affiliates or third parties have not entered into any new business relationships, including contracts to supply products or services, joint venture agreements and licensing agreements during the month of **November 2018**.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced, expired or were terminated during the month of **November 2018**.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no asset acquisitions or dispositions by the Issuer during the preceding month of **October 2018**.

8. Describe the acquisition of new customers or loss of customers.

There were no acquisitions of new customers or loss of customers during the month of **November 2018**.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks during the month of **November 2018**.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of **November 2018**.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of November 2018.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became party to during the month of November 2018.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no indebtedness incurred or repaid by the Issuer during the month of November 2018.

14. Provide details of any securities issued and options or warrants granted.

During the month of November 2018, the following securities were issued:

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Stock Options	300,000 Stock Options to purchase 300,000 Common shares issued at a price of \$0.37 per Common share for a period of two years from grant	Issued to Chris Koon, a member of the Issuer's advisory board.	Proceeds received from the exercise of Stock Options will be used for general working capital.
Common Shares	125,000 Common shares	Exercise of warrants	\$9,375 received from the exercise of warrants will be used towards general working capital.

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons of the Issuer during the month of November 2018.

16. Provide details of any changes in directors, officers or committee members.

As at the date of this report, the directors and officers of the Issuer were as follows:

Konstantin Lichtenwald – Director

Christopher Miller – Director, Chief Executive Officer and interim Corporate Secretary

Erik LeVang – Director

Jeff Koslosky – Chief Operating Officer

Johannes (Theo) van der Linde – Chief Financial Officer

Gina Burrus - Vice President of Sales

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion and Analysis for the three months ended August 31, 2018 dated as of October 30, 2018 (the "MD&A") under the headings "FINANCIAL INSTRUMENTS", "OTHER RISKS AND UNCERTAINTIES" and "RISKS AND UNCERTAINTIES". The MD&A is available on the Issuer's SEDAR profile at www.sedar.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 18, 2018.

Christopher Miller
 Name of Director or Senior
 Officer

"Christopher Miller"
 Signature
Chief Executive Officer
 Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer	November 2018	YY/MM/D 18/12/18
Koios Beverage Corp.		
Issuer Address		
Suite 810 – 789 West Pender St.,		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6Z 2R9	(604) 687-3141	(604) 725-1857
Contact Name	Contact Position	Contact Telephone No.
Christopher Miller	CEO	(303) 946-2728
Contact Email Address	Web Site Address	
Chris@koiosbeveragecorp.com	www.mentaltitan.com	